The Board of Trustees of the Leland Stanford Junior University
发明人:
Samuel Strober,Robert Lowsky
申请号：
GB201704460
公开号：
GB2558680A
申请日:
2014.02.07
申请国别(地区):
GB
年份:
2018
代理人:
摘要：
An organ donor-derived composition of engineered hematopoietic cells comprising at least 1 x 106 CD34+ cells/kg recipient weight and at least 1 x 106 CD3+ T cells/kg recipient weight for use in organ transplantation to an HLA-mismatched recipient preferably allows withdrawal of immunosuppressive drugs without rejection. The administration of said composition of engineered hematopoietic cells comprises: (a) implanting an organ in a recipient of said organ transplantation； (b) treating said recipient of said organ transplantation with a non-myeloablative conditioning； (c) infusing said recipient of said organ transplantation with said composition of engineered hematopoietic cells as set forth in any of the preceding claims； and (d) maintaining said recipient of said organ transplantation on an immunosuppressive regimen for a period of time sufficient to develop a mixed chimerism for at least six months.
